CFO  News Hubb
Advertisement
  • Home
  • CFO News
  • Financial Advisor
  • Financial Planning
  • Markets News
  • Economics
  • Contact
No Result
View All Result
  • Home
  • CFO News
  • Financial Advisor
  • Financial Planning
  • Markets News
  • Economics
  • Contact
No Result
View All Result
CFO  News Hubb
No Result
View All Result
Home CFO News

DEA Pressed ADHD-Drug Makers About Impact of Telehealth Firms on Surging Demand

by admin
December 31, 2022
in CFO News



The Drug Enforcement Administration told makers of medication for attention-deficit hyperactivity disorder that it was concerned that “aggressive marketing practices” by companies including telehealth providers could be driving excessive prescriptions, according to a letter from the agency.

While the letter doesn’t cite specific companies, it reflects the DEA’s concerns about marketing efforts for ADHD treatment by telehealth companies such as Cerebral Inc. and Done Global Inc., whose prescribing practices the agency has been investigating. The DEA said in December that it wouldn’t allow any increase in 2023 production of pharmaceutical ingredients that go into Adderall and other stimulants used to treat ADHD. The letter, reviewed by The Wall Street Journal, was sent to drugmakers over the summer but hasn’t previously been reported.



Source link

Previous Post

Roth IRA Rules + Contribution Limits [2023 Update]

Next Post

Links 12/31/2022 | naked capitalism

TRENDING

January jobs seen slowing slightly, but impact of big layoffs unclear
Markets News

January jobs seen slowing slightly, but impact of big layoffs unclear

February 4, 2023
Economics

Words, Numbers, and Samuel Gregg

February 4, 2023
Economics

Labor market off to a strong start in 2023: 517,000 jobs added in January as unemployment rate hits historic low

February 4, 2023
Economics

James Galbraith: The Quasi-Inflation of 2021-2022 – A Case of Bad Analysis and Worse Response

February 4, 2023
Financial Advisor

Modi Is Hurting Himself by Brawling With the BBC

February 4, 2023

© 2022 CFO News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • CFO News
  • Financial Advisor
  • Financial Planning
  • Markets News
  • Economics
  • Contact

Newsletter Sign Up

No Result
View All Result
  • Home
  • CFO News
  • Financial Advisor
  • Financial Planning
  • Markets News
  • Economics
  • Contact

© 2022 CFO News Hubb All rights reserved.